Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling.

Abstract : The identification of one mechanism that causes vision loss in inherited degenerative retinal disorders revealed a new signaling molecule that represents a potential therapy for these currently untreatable diseases. This protein, called rod-derived cone viability factor (RdCVF), maintains the function and consequently the viability of cone photoreceptor cells in the retina; mice that lack this factor exhibit a progressive loss of photoreceptor cells. The gene encoding RdCVF also encodes, by differential splicing, a second product that has characteristics of a thioredoxin-like enzyme and protects both photoreceptor cells and, more specifically, its interacting protein partner, the tau protein, against oxidative damage. This signaling pathway potentially links environmental insults to an endogenous neuroprotective response.
Type de document :
Article dans une revue
Science Translational Medicine, American Association for the Advancement of Science, 2010, 2 (26), 26ps16. 〈10.1126/scitranslmed.3000866〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00472434
Contributeur : Katia Marazova <>
Soumis le : lundi 12 avril 2010 - 10:09:59
Dernière modification le : vendredi 31 août 2018 - 09:13:20
Document(s) archivé(s) le : mardi 14 septembre 2010 - 18:09:48

Fichiers

226ps16-F2_.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Thierry Léveillard, José-Alain Sahel. Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling.. Science Translational Medicine, American Association for the Advancement of Science, 2010, 2 (26), 26ps16. 〈10.1126/scitranslmed.3000866〉. 〈inserm-00472434〉

Partager

Métriques

Consultations de la notice

183

Téléchargements de fichiers

609